MedWatch

Eli Lilly lowers guidance for 2021

In spite of its growing revenue and positive Trulicity sales, Eli Lilly has opted to lower its 2021 guidance, according to the firm's quarterly report for the first three months of the year.

Photo: Mike Blake/Reuters/Ritzau Scanpix

Read this article for free

Register with your E-mail.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Ambu fails to live up to revenue forecasts

The number of endoscopes sold is significantly higher than what the market had predicted in Ambu's second quarter. However, this has not brought about the kind of revenue that analysts had expected. The full-year outlook is maintained.

Tough competition forces innovation at Ambu

Ambu is intensifying its efforts to create the next generation of its duodenoscopes. A number of competitors are circling, and an upcoming tender is a good opportunity for income. CEO Juan Jose Gonzalez calls the new duodenoscope the biggest earner of the future.

Analyst on new Bose hearing aid: "Won't disrupt Danish manufacturers"

US electronics company Bose's announced launch of a new, cheap self-tuning hearing aid won't cause sales to plummet for established hearing aid manufacturers, analysts believe. Demant welcomes the competition and WSA plans to test Bose's new solution to understanding its technology.

Further reading

Related articles

Latest news

See all jobs